Study
|
Study Design
|
Population
|
Patienta
|
Treatments
|
Jadad score
|
Total (% male)
|
Agesb
|
Simons, 2004 [17]
|
Randomized double-blind placebo-controlled study
|
DM or metabolic syndrome
|
ES: 92 (62.0)
S: 99 (60.0)
|
64
63
|
Ongoing statin with ezetimibe or placebo for 8 weeks
|
3
|
Gaudiani, 2005 [18]
|
Randomized double-blind multicenter study
|
LDL-C > 100 mg/dl and TG < 600 mg/dl with type 2 DM
|
ES: 104 (59.8)
S: 110 (55.5)
|
57.8
58.3
|
Simvastatin 40 mg or ezetimibe + simvastatin 20 mg daily for 6 weeks
|
3
|
Denke, 2006 [19]
|
Randomized double-blind placebo-controlled multicenter study
|
DM, metabolic syndrome without diabetes, or neither disorder who had LDL-C levels exceeding NCEP-ATP III goals
|
ES: 768 (49.7)
S: 396 (46.8)
|
61.7 ± 11.1
60.9 ± 11.4
|
Ongoing statin with ezetimibe or placebo for 6 weeks
|
3
|
Goldberg, 2006 [20]
|
Randomized double-blind multicenter study
|
Type 2 DM
|
494 (44.7)
|
59.3 ± 10.2
|
Atorvastatin 10, 20 or 40 mg, ezetimibe + simvastatin 10 mg, or ezetimibe + simvastatin 40 mg daily for 6 weeks
|
4
|
Constance, 2007 [21]
|
Randomized double-blind active-controlled study
|
Type 2 DM
|
ES: 220 (50.9); 222 (50.5)
S: 219 (49.3)
|
62.1
62.4
61.7
|
Atorvastatin 20 mg, ezetimibe + simvastatin 20 mg or ezetimibe + simvastatin 40 mg daily for 4 weeks
|
5
|
Settergren, 2008 [22]
|
Randomized double-blind controlled study
|
Type 2 DM or IGT and carotid artery disease
|
ES: 19 (58.0)
S: 20 (75.0)
|
74
70
|
Simvastatin 80 mg or ezetimibe + simvastatin 10 mg daily for 6 weeks
|
5
|
Polis, 2009 [23]
|
Randomized double-blind controlled multicenter study
|
DM or metabolic syndrome
|
Study 1
ES: 221 (47.1)
S: 207 (46.4)
Study 2
ES: 190 (51.1)
S: 185 (40.5)
|
60.8 ± 10.4 59.9 ± 9.3
57.7 ± 10.2
57.8 ± 9.7
|
Atorvastatin 10, 20, 40 or 80 mg or ezetimibe + atorvastatin 10-80 mg daily for 6 weeks (study 1); rosuvastatin 10, 20 or 40 mg or ezetimibe + simvastatin 10-80 mg daily for 6 weeks (study 2)
|
4
|
Bardini, 2010 [24]
|
Randomized double-blind, placebo-controlled multicenter study
|
Type 2 DM and CHD
|
ES: 37 (56.8)
S: 50 (76.0)
|
65 ± 6.5
64 ± 6.1
|
Simvastatin 40 mg or ezetimibe + simvastatin 20 mg daily for 6 weeks
|
5
|
Ruggenenti, 2010 [25]
|
Randomized double-blind controlled study
|
Type 2 DM with total cholesterol > 135 mg/dl despite lipid-lowering therapy
|
ES: 54 (63.0)
S: 54 (55.6)
|
65.7
65.2
|
Simvastatin 40 mg or ezetimibe + simvastatin 40 mg daily for 6 weeks
|
5
|
Kawagoe, 2011 [26]
|
Randomized controlled study
|
DM or IGT
|
ES: 12 (50.0)
S: 12 (41.7)
|
64.2 ± 7.2
65.1 ± 7.2
|
Fluvastatin 60 mg or ezetimibe + fluvastatin 20 mg daily for 10 weeks
|
2
|
Uemura, 2012 [27]
|
Randomized open-label cross-over study
|
Type 2 MD or IGT, and carotid artery disease
|
39
|
67.8 ± 9.7
|
Atorvastatin 20 mg or ezetimibe + atorvastatin 10 mg daily for 12 weeks
|
2
|
Vaverkova, 2012 [28]
|
Randomized double-blind active-controlled multicenter study
|
High cardiovascular risk with CHD, established vascular
atherosclerotic disease, or type 2 DM
|
ES: 100 (58.0)
S: 82 (54.9)
|
63.1 ± 8.6
64.5 ± 9.1
|
Rosuvastatin 10 mg or ezetimibe + simvastatin 20 mg daily for 6 weeks
|
4
|
Rosen, 2013 [29]
|
Randomized double-blind active-controlled study
|
Type 1 or 2 DM and symptomatic cardiovascular disease
|
808 (52.2)
|
64.0 ± 8.5
|
Rosuvastatin 10 mg, doubling statin or ezetimibe + simvastatin 20 mg daily for 12 weeks
|
5
|
Torimoto, 2013 [30]
|
Randomized open-label controlled study
|
Type 2 DM
|
ES: 39 (62.0)
S: 36 (44.0)
|
66.3 ± 11.7
63.0 ± 13.0
|
Rosuvastatin 5 mg or ezetimibe + rosuvastatin 2.5 mg daily for 12 weeks
|
3
|
Villegas-Rivera, 2015 [31]
|
Randomized double-blind placebo-controlled study
|
Type 2 DM and diabetic polyneuropathy
|
ES: 25 (40.0)
S: 25 (48.0)
|
55.0 ± 12.0
54.0 ± 10.5
|
Rosuvastatin 20 mg or ezetimibe + rosuvastatin 20 mg daily for 16 weeks
|
5
|
Sakamoto, 2017 [32]
|
Randomized open-label controlled multicenter study
|
Type 2 DM and failed to reach target LDL-C values
|
ES: 53 (58.5)
S: 56 (57.1)
|
61.7 ± 11.1
62.6 ± 9.5
|
Ongoing statin (atorvastatin 10 mg, pitavastatin 1 mg) with ezetimibe or doubling statin (atorvastatin 20 mg, pitavastatin
2 mg) for 12 weeks
|
3
|
El-Tamalawy, 2018 [33]
|
Randomized controlled study
|
Type 2 DM or IGT and atherosclerosis
|
ES: 20 (55.0)
S: 20 (70.0)
|
61.0 ± 7.1
62.0 ± 6.9
|
Doubling atorvastatin or ezetimibe + atorvastatin 40 mg daily for 3 months
|
2
|